Jounce Therapeutics, Inc. (NasdaqGS: JNCE) Loss Submission Form

Kuznicki Law is investigating the proposed merger of Jounce Therapeutics, Inc. (the “Company”) (NasdaqGS: JNCE) with Redx Pharma Plc. Under the terms of the proposed transaction, Jounce shareholders will end up owning approximately 37% of the share capital of the combined group. Kuznicki law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.